Downregulated expression of miR-503 predicts poor prognosis in prostate cancer patients.
Overexpression of miR-503 suppresses the growth of prostate cancer cells in vitro and in vivo.
miR-503 inhibits ZNF217 expression to promote PCa progression.
Aberrant expression of GATA3 mediates PCa progression by targeting miR-503/ZNF217.